Ralfinamide

Ralfinamide is a Drug action#The [specificity of drugs|multimodal] drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain.
It has a relatively complex pharmacology, acting as a mixed voltage-gated [sodium channel] blocker, N-type [calcium channel] blocker, noncompetitive NMDA receptor antagonist, and monoamine oxidase B inhibitor.
As of 2020, it was in Phase [III clinical trials|phase III] clinical trials. In 2010 it failed a phase II trial for lower back pain. Encouraging Phase II results have been announced for neuropathic pain.